Bausch + Lomb Corporation filed an amendment to report that Thomas J. Appio succeeded Brent Saunders as Chairman of the Board effective August 10, 2026, while Mr. Saunders continues serving on the board. The company also appointed Robert Chersi, Laurence Paul, M.D., and Barbara Trebbi to its committees with specific chair roles: Dr. Paul leads the Nominating and Corporate Governance Committee, Eduardo Alfonso chairs the Science and Technology Committee, and Ms. Trebbi chairs the Talent and Compensation Committee. These changes follow earlier resignations and appointments announced on August 6, 2026. Bausch + Lomb Corporation operates in the healthcare industry, specializing in eye health products including contact lenses and ophthalmic pharmaceuticals.

Bausch + Lomb Corporation appointed four new directors—Thomas J. Appio, Robert Chersi, Laurence Paul, M.D., and Barbara Trebbi—to its board effective August 5, 2026, replacing Steven H. Collis, Karen L. Ling, Thomas W. Ross, Sr., and Andrew C. von Eschenbach, M.D. The new appointments were made at the request of controlling shareholder Bausch Health Companies Inc. Resigning directors received prorated compensation and accelerated vesting of unvested restricted stock units; Mr. Ross entered a one-year consulting agreement with a $400,000 fee. The company reported second-quarter revenue of $1.394 billion, an 8% increase on a constant currency basis, and reaffirmed full-year 2026 guidance for revenue between $5.440 billion and $5.540 billion. Bausch + Lomb Corporation is a global eye health company that manufactures contact lenses, surgical devices, and pharmaceutical products.

Bausch + Lomb Corporation reported second-quarter 2026 results on July 29, 2026, with revenue of $1.394 billion, representing a 9% increase as reported and 8% on a constant currency basis compared to the prior year period. The company posted a GAAP net loss of $14 million, or ($0.04) per share, against an adjusted EBITDA of $241 million. Management raised full-year 2026 revenue guidance to $5.44 billion–$5.54 billion and adjusteded EBITDA excluding acquired IPR&D guidance to $1.025 billion–$1.075 billion, citing broad-based growth across Surgical and Pharmaceuticals segments. The company also announced positive top-line results from a pivotal clinical study for its investigational enVista Beyond intraocular lens. Bausch + Lomb operates in the eye health industry, manufacturing contact lenses, surgical devices, and pharmaceuticals.